Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02414776

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy — ABC01  

Estrogen Receptor Positive Breast Cancer Clinical Trial

Official title:
Phase Ib/II Study of Hydroxychloroquine in Metastatic ER-Positive Breast Cancer Progressing on Hormonal Therapy

Clinical Trial Summary

To determine the safety and tolerability of orally administered hydroxychloroquine with hormonal therapy.

To assess the response rate of hydroxychloroquine in combination with hormonal therapy.

Clinical Trial Description

To determine the number of patients with adverse effects

To assess the clinical response to the combination ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02414776
Study type Interventional
Source Western Regional Medical Center
Contact
Status Terminated
Phase Phase 1
Start date July 2014
Completion date November 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01984138 - REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Phase 2
Active, not recruiting NCT01996046 - FDG PET/CT in Breast Cancer Bone Mets
Completed NCT01219699 - A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene Phase 1
Active, not recruiting NCT02409316 - [18F]FES PET/CT in Endocrine Refractory Breast Cancer Phase 2
Active, not recruiting NCT01992952 - Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer Phase 1/Phase 2
Recruiting NCT04727632 - [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial Early Phase 1
Terminated NCT02000375 - A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) Phase 2
Active, not recruiting NCT02668666 - Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Phase 2
Completed NCT02820961 - Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer Phase 1
Active, not recruiting NCT02947685 - Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Phase 3
Terminated NCT02823262 - A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older N/A
Active, not recruiting NCT02216786 - A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer Phase 2
Active, not recruiting NCT01765049 - Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor
Active, not recruiting NCT00066690 - Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Phase 3
Active, not recruiting NCT02238808 - A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers Phase 2
Completed NCT02988986 - TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Phase 2